Axogen stock: recent moves and what they might mean for investors

Axogen (AXGN) stock has drawn fresh attention after recent trading left it around $40.99, with returns over the past month and past 3 months offering a clearer snapshot of how the market currently prices its peripheral nerve repair business.

Recent trading has been choppy in the very short term, with the 7 day share price return down 2.54%. However, the 30 day and year to date share price returns of 17.92% and 32.23% point to building momentum on top of a very strong 1 year total shareholder return of 246.49% and a 3 year total shareholder return of more than 3x.

If Axogen’s move has you thinking about what else is setting the pace in healthcare, it may be worth scanning 32 healthcare AI stocks

With Axogen posting strong recent returns but still trading below the average analyst price target, the key question is simple: is the stock mispriced today or already reflecting much of its potential future growth?

Most Popular Narrative: 19.3% Undervalued

Axogen's most followed valuation narrative places fair value at about $50.78 per share, compared with the recent close of $40.99, framing the stock as materially mispriced on that view.

Upcoming FDA Biologics License Application (BLA) approval for Avance Nerve Graft in September 2025 is expected to secure 12 years of market exclusivity and establish Avance as the only biologic with this indication, which should drive pricing power, limit biosimilar competition, and boost both gross margin and long-term earnings visibility.

Want to see how one core product, ambitious revenue targets and rising margin expectations all feed into that fair value estimate? The assumptions behind that price target rely on a long runway of compound growth, a step change in profitability and a future earnings multiple that stands well above the sector norm.

The narrative applies a discount rate of 7.79% to Axogen's projected cash flows and earnings, and ties its $50.78 fair value to expectations for faster revenue expansion, a move from loss making to profitability and a rich future P/E multiple relative to the broader US medical equipment group. It also factors in analyst views on how much additional stock may be issued over time and how margins might evolve as Avance scales.

Result: Fair Value of $50.78 (UNDERVALUED)

However, this hinges on Avance’s BLA process going smoothly and on Axogen translating payer coverage into real procedure volume, both areas where setbacks could quickly challenge the upside story.

Another angle on valuation

Those fair value narratives paint Axogen as 19.3% undervalued, but the current P/S ratio of 9.2x tells a different story. That is well above the US Medical Equipment industry at 2.7x, the peer average at 4x, and even the 4.3x fair ratio that the market could potentially move toward over time.

Put simply, the stock already carries a rich revenue multiple. This raises the risk that any slip in growth, margins or regulatory progress could hit the share price harder than a lower rated peer. How comfortable are you with paying this kind of premium?

Next Steps

With such a mix of optimism and caution around Axogen, it makes sense to look at the numbers yourself and decide how you feel about the balance of risk and reward. To weigh both sides in one place, start with the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If Axogen has sharpened your thinking, now is the moment to widen your net and line up a few more stocks that might deserve a closer look.

• Target sturdier cash flows by checking out companies in the 50 high quality undervalued stocks that pair quality fundamentals with prices below what some investors might expect.
• Prioritise resilience by scanning the 66 resilient stocks with low risk scores so you are not missing stocks that score well on financial strength and risk factors.
• Get ahead of the crowd by reviewing the screener containing 22 high quality undiscovered gems before these quieter opportunities land firmly on everyone else’s radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.